PMS-PIOGLITAZONE TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
14-05-2018
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)
Beschikbaar vanaf:
PHARMASCIENCE INC
ATC-code:
A10BG03
INN (Algemene Internationale Benaming):
PIOGLITAZONE
Dosering:
30MG
farmaceutische vorm:
TABLET
Samenstelling:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100
Prescription-type:
Prescription
Therapeutisch gebied:
THIAZOLIDINEDIONES
Product samenvatting:
Active ingredient group (AIG) number: 0141541002; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2007-12-05
Productkenmerken
PRODUCT MONOGRAPH
PR
PMS-PIOGLITAZONE
Pioglitazone Hydrochloride Tablets
15 mg, 30 mg, 45 mg
USP
Anti-Diabetic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
May 14, 2018
www.pharmascience.com
Submission Control No: 215147
_pms-PIOGLITAZONE Product Monograph _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
15
OVERDOSAGE
.......................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 17
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL TRIALS
..........................................................
Lees het volledige document
